PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsNew drug to treat female reproductive problems and improve fertility

BioNews

New drug to treat female reproductive problems and improve fertility

Published 20 November 2020 posted in News and appears in BioNews 1073

Author

Bethany Muller

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.

A new drug that may be able to improve fertility for women with ovulatory problems has been showcased by researchers at Imperial College London...

A new drug that may be able to improve fertility for women with ovulatory problems has been showcased by researchers at Imperial College London.

The drug, called MVT-602, works by modifying the activity of kisspeptin, making it more potent, stable and water-soluble. Kisspeptin is an important reproductive hormone involved in the release of two other hormones from the pituitary gland  – luteinizing hormone (LH) and follicle stimulating hormone (FSH) – that regulate maturation and release of egg cells.

'This is the first study to show that a single dose of MVT-602 can induce a longer duration of hormonal stimulation in women than naturally occurring kisspeptin,' said study author Dr Ali Abbara, National Institute for Health Research (NIHR) clinician scientist at Imperial College London. 'Therefore, it reveals exciting potential to treat a range of reproductive health conditions using MVT-602 and offer women improved treatment options.'

In the study, published this week in the Journal of Clinical Investigations, twenty-four women were injected with the drug and their levels of LH and FSH were measured over several days. Twelve of the women had no ovulatory problems; six had hypothalamic amenorrhea (HA), characterised by a lack of ovulation; and six had polycystic ovarian syndrome (PCOS), an endocrine disorder which presents with enlarged ovaries and irregular periods.

The drug was able to stimulate a similar LH peak to kisspeptin alone in all groups, but showed a longer duration of action – with the peak remaining high for an extended time. A particularly strong response was observed in women with HA.

Previous work has shown that kisspeptin is able to stimulate ovarian function for IVF treatment, without increasing the risk of ovarian hyperstimulation syndrome (OHSS). However, the effect of kisspeptin is short-lasting and frequent administration reduces its effectiveness, limiting its applicability. The authors suggest MVT-602 application may be able to improve its application.

'Our previous work showed that kisspeptin can be used to stimulate ovulation in women undergoing IVF treatment, but there are some limitations on using the naturally occurring kisspeptin hormone as its effectiveness wares off after a few hours,' said lead author Professor Waljit Dhillo, research professor in endocrinology and metabolism at Imperial College London. 'This study suggests that MVT-602 can stimulate kisspeptin over a longer period of time with no side effects, which means we could potentially use it to treat a wider range of reproductive disorders.'

It is important to note this is a small study and further work is needed. Dr Bassel Wattar, NIHR academic clinical lecturer in women's health at the University of Warwick, who was not involved in the study said: 'Though promising, the findings are very early and experimental, far away from being used in clinical practice to help subfertile women with ovulatory problems.'

Sources and References

  • 16/11/2020
    Imperial College London
    New drug can improve fertility in women with reproductive health problems
  • 16/11/2020
    The Journal of Clinical Investigation
    Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders
  • 17/11/2020
    Open Access Government
    New kisspeptin drug could treat polycystic ovary syndrome
  • 19/11/2020
    First Post
    New drug can help treat reproductive health conditions like PCOS, improve fertility in women

Related Articles

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
27 June 2022 • 2 minutes read

Fibrosis drugs reverse ovarian ageing in mice

by Dr Rachel Montgomery

Ovarian ageing in mice has been shown to be reversible using compounds that target fibrosis and promote mitochondrial health..

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
29 June 2021 • 2 minutes read

Two egg collections in one cycle may benefit some IVF patients

by Jen Willows

A protocol involving two egg collections in the same menstrual cycle may reduce the time to pregnancy for IVF patients who respond poorly to ovarian stimulation...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
26 June 2020 • 2 minutes read

Polycystic ovary syndrome may have more than two different subtypes

by Dr Kimberley Bryon-Dodd

There may be at least two different biologically relevant subtypes of polycystic ovary syndrome (PCOS)...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
3 May 2019 • 2 minutes read

Gene behind major cause of women's infertility found

by Jakki Magowan

A gene that plays a key role in causing polycystic ovary syndrome (PCOS) has been discovered, and could lead to better disease prediction and treatment...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
18 May 2018 • 2 minutes read

Hopes for PCOS cure as scientists reveal cause in mice

by Dr Elizabeth Oliver

Polycystic ovary syndrome (PCOS) may be due to a hormone imbalance before birth, recent research has revealed...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« IVF does not increase long-term risk of ovarian cancer

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Complex structures of the human heart bioengineered

8 August 2022 • 1 minute read

Brain tumour gene also linked to childhood cancers

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856